NEUROONE MEDICAL TECHNOLOGIES Corp (NMTC) stock
Close on Nov 11, 2026Market cap $7.31MP/E –Yield –
NEUROONE MEDICAL TECHNOLOGIES Corp grew revenue 42.8% to $9.47M over the twelve months to Jun 30, 2026. Free cash flow was -$7.16M. At the latest close the market valued the company at $7.31M.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $7.31M
- P/E ratio
- –
- Price to sales
- 0.77
- Price to book
- 1.94
- Dividend yield
- –
- Free cash flow yield
- -98.02%
Fundamentals
- Revenue
- $9.47M
- Net income
- -$7.45M
- EPS, diluted
- -$0.93
- Free cash flow
- -$7.16M
- Book value per share
- $0.43
- Diluted shares
- 9M
Trading
- Next earnings
- Feb 16, 2027 (estimated, before the open)
- Previous close
- $0.78
- Open
- $0.76
- Day's range
- $0.75 – $0.82
- Volume
- 14,875
- Average volume (20 days)
- 75,292
- Beta (5 years)
- 0.72
- 52-week range
- $0.75 – $6.12
- RSI (14 days)
- 36.0
- Volatility (1 year)
- 84.8%
- Relative volume
- 0.06×
- WACC
- 8.5%
Market cap history
Month-end market cap since 2017, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | NMTC | S&P 500 | Difference | NMTC per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -28.4% | -2.4% | −25.9 pts | ||
| 3 months | -49.9% | -1.2% | −48.7 pts | ||
| Year to date | -82.4% | +12.3% | −94.6 pts | ||
| 1 year | -81.7% | +12.4% | −94.2 pts | ||
| 3 years | -89.9% | +78.8% | −168.7 pts | -53.4% | +21.4% |
| 5 years | -95.0% | +75.2% | −170.2 pts | -45.1% | +11.9% |
Fifteen years at a glance
Fiscal years 2009 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Neuroone Medical Technologies filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- News
- Results
- Update
- Results
- Results
About Neuroone Medical Technologies
Surgical & Medical Instruments & Apparatus
NeuroOne Medical Technologies Corporation is a medical technology company that develops thin-film electrode technologies for diagnostic, ablation, and stimulation applications. Its offerings target brain-related conditions, including epilepsy and Parkinson’s disease, as well as pain management and targeted drug delivery. The company’s commercialized devices include Evo Cortical and Evo sEEG electrodes for subsurface and brain-surface monitoring and stimulation, along with the OneRF Brain Ablation System and the OneRF TN Ablation System for nerve lesioning and chronic facial pain relief. It also actively designs combination devices for spinal cord stimulation, basivertebral nerve ablation, and preclinical therapeutic delivery. NeuroOne serves healthcare providers, including pain management physicians and surgeons, alongside commercial and biopharmaceutical partners such as Zimmer Biomet Holdings, Inc.
Company profile, executives and historyNeuroone Medical Technologies stock: common questions
What is Neuroone Medical Technologies's stock price?
NMTC closed at $0.80 on Nov 11, 2026, up 3.26% on the day. Over the past 52 weeks it traded between $0.75 and $6.12.
What is Neuroone Medical Technologies's market cap?
Neuroone Medical Technologies was worth $7.31M at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is NMTC's P/E ratio?
Neuroone Medical Technologies lost money over the twelve months to Jun 30, 2026 (diluted EPS -$0.93), so it has no meaningful P/E ratio.
How much revenue does Neuroone Medical Technologies make?
Neuroone Medical Technologies reported revenue of $9.47M for the twelve months to Jun 30, 2026, up 42.8% from a year earlier.
Does Neuroone Medical Technologies pay a dividend?
No. Neuroone Medical Technologies has not paid a cash dividend over the last twelve months.
When does Neuroone Medical Technologies report earnings next?
Neuroone Medical Technologies is expected to report Q1 FY2027 results on Feb 16, 2027, before the open. The date is estimated from its past reporting pattern until the company confirms it.
How has NMTC stock performed over the past year?
Including dividends, NMTC returned -81.7% over the past year, against +12.4% for the S&P 500.
How many NMTC shares are sold short?
0M shares were sold short at the latest FINRA report, 15.58% of the float, or 2.4 days of average trading volume.
Who are Neuroone Medical Technologies's competitors?
Companies most similar to Neuroone Medical Technologies by business, industry and size include EBRCZ, NSPR, ECIA, NRXS, CLPT.
See a number that looks wrong?